MIAMI, FL & CHICAGO, IL – April 28, 2023 – Miami Cancer Institute, part of Baptist Health South Florida, today announced its oral and poster presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, at McCormick Place in Chicago, Illinois. The presentations focus on brain metastases; sarcomatoid and classic urothelial bladder cancer; lepomeningeal disease; lung cancer; and glioblastoma, among others.
“I could not be more excited about this impressive roster of oral and poster presentations at the 2023 ASCO Annual Meeting, one of the most prestigious events in oncology research,” said Manmeet S. Ahluwalia, M.D., M.B.A., FASCO, chief of medical oncology, chief scientific officer, deputy director, and Fernandez Family Foundation Endowed Chair in Cancer Research at Miami Cancer Institute. “Miami Cancer Institute researchers will present the latest findings in some of the most promising fields of cancer research. Our presentations will include novel treatments and diagnostic methods, outcomes data, and results from a public awareness campaign.”
Miami Cancer Institute researchers will give one oral, eight poster, and eight online presentations at ASCO 2023:
Oral Presentation
Friday, June 2, 2023
Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective Phase 2 trial
Speaker: Rupesh R. Kotecha, M.D.
Time: 2:57 p.m. CT
Location: S100a
Poster Presentations
Saturday, June 3, 2023
Survival outcomes of sarcomatoid versus classic urothelial carcinoma of bladder
Presenter: Rohan Garje, M.D.
Time: 8:00 a.m. CT
Location: Hall A
Number: 80
Survival outcomes of micropapillary versus classic variant, loco-regional bladder cancer: A 2004-2019 National Cancer Database analysis
Presenter: Rohan Garje, M.D.
Time: 8:00 a.m. CT
Location: Hall A
Number: 84
Enhancing lung cancer screening through “Saved by the Scan”: lessons from a multipronged public service advertising program
Presenter: Atulya Aman Khosla, M.D.
Time: 1:15 p.m. CT
Location: Hall A
Number: 208
Evaluating the diagnostic performance of leptomeningeal diagnosis with CNSide™ compared to standard cytology
Presenter: Haley Appel, PA-C
Time: 1:15 p.m. CT
Location: Hall A
Number: 385
Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry
Presenter: Ahmad Ozair, M.D.
Time: 1:15 p.m. CT
Location: Hall A
Number: 395
Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report
Presenter: Manmeet Singh Ahluwalia, M.D., MBA, FASCO
Time: 1:15 p.m. CT
Location: Hall A
Number: 417
Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report
Presenter: Manmeet Singh Ahluwalia, M.D., MBA, FASCO
Time: 1:15 p.m. CT
Location: Hall A
Number: 424
Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE)
Presenter: Manmeet Singh Ahluwalia, M.D., MBA, FASCO
Time: 1:15 p.m. CT
Location: Hall A
Number: 439a
Miami Cancer Institute research was also selected for numerous 2023 ASCO Annual Meeting online publications, which can be found on the ASCO 2023 Annual Meeting website.
For updates from the 2023 ASCO Annual Meeting, look for #ASCO2023 on social media and follow Miami Cancer Institute on Twitter at @MiamiCancerInst.
###
About Miami Cancer Institute
Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK. For more information, please visit https://cancer.baptisthealth.net/miami-cancer-institute.
Miami Cancer Institute is part of Baptist Health Cancer Care, the largest cancer program in South Florida, with locations from the Florida Keys to the Palm Beaches.
